A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by stimulating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with immediate protection from the point of delivery, exactly when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Antibodies from the mother passed through the placenta protect newborns from day one
- Coverage achievable with two-week gap before premature birth
- Vaccination during third trimester still provides significant protection for infants
Compelling evidence from recent research
The efficacy of the RSV vaccine administered during pregnancy has been confirmed through a extensive research programme carried out throughout England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing strong and reliable evidence of the vaccine’s practical effectiveness. The study’s findings have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The breadth of this investigation offers healthcare professionals and parents-to-be with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results paint a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers had not been given the vaccination. This clear distinction underscores the vaccine’s essential role in reducing the risk of serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research analysed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospitalisations. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology assessed real-world outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine performs when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe effectively. Parents often witness their babies struggling visibly, their chests rising whilst they attempt to draw enough air into their compromised lungs. Whilst most infants recover with palliative treatment, a small but significant number die from RSV-related complications yearly, making vaccination as prevention a vital health service objective for safeguarding the most vulnerable and youngest members of society.
- RSV triggers inflammation in lungs, resulting in serious respiratory problems in infants
- Approximately half of newborns contract the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV annually
- Small numbers of babies succumb to RSV complications annually in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the value of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for ensuring newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.
The messaging from public health bodies stays clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts launching diverse outreach initiatives to reach women during pregnancy
- Regional disparities in vaccine uptake rates in different parts of England demand focused enhancement
- Local healthcare systems tailoring initiatives to meet local requirements and situations
Practical implications and parental perspectives
The vaccine’s impressive effectiveness delivers concrete gains for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the launch of this protective measure, the 80% decrease in admissions represents thousands of infants shielded from critical disease. Parents no more face the upsetting situation of watching their newborns struggle for breath or struggle to eat, symptoms that mark serious RSV disease. The vaccine has substantially transformed the terrain of neonatal breathing health, giving expectant mothers a preventative option to protect their most at-risk babies during those vital initial period.
For families like that of Malachi, whose serious RSV infection led to severe brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s promotion of the jab emphasises the profound consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to women in pregnancy during their third trimester, converting what was once an inevitable seasonal threat into a manageable health risk.